Health-related quality of life after myocardial infarction, does choice of method make a difference?

Scand Cardiovasc J. 2014 Aug;48(4):216-22. doi: 10.3109/14017431.2014.923581. Epub 2014 Jun 26.


Objectives: The aim of this study was to compare health-related quality of life (HRQoL) scores obtained from the instrument Short Form (SF)-36 through the so-called SF-6D utilities, and those obtained from 15D, in patients with ST-elevation myocardial infarction (STEMI), and to evaluate the consequences in estimation of quality adjusted life years (QALYs).

Design: This was a sub-study of the Norwegian District Treatment of STEMI, in which patients with STEMI treated with tenecteplase, were randomized to early angioplasty or standard management (n = 266). HRQoL data were collected at all visits (0, 1, 3, 7 and 12 months). All patients with complete data were included (n = 248).

Results: The score range was 0.33-1.0 for SF-6D and 0.49-1.0 for 15D. Mean utility scores from 15D were higher and had different distribution compared to scores from SF-6D. Mean QALY for the whole group was higher using 15D than SF-6D (0.89 vs. 0.77). The incremental number of QALYs with early angioplasty compared to standard treatment was 0.005 (95% CI: - 0.018 to 0.028) using SF-6D, and 0.004 (95% CI: - 0.010 to 0.018) using the 15D instrument.

Conclusions: Choice of instrument may influence HRQoL scores, but not necessarily the gain in QALYs.

Trial registration: NCT00161005.

Keywords: SF-6D; Sintonen 15D; coronary heart disease; quality of life; quality-adjusted life years; randomized controlled trial.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Angioplasty
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / diagnosis
  • Myocardial Infarction / psychology*
  • Myocardial Infarction / therapy
  • Norway
  • Predictive Value of Tests
  • Prospective Studies
  • Quality of Life*
  • Quality-Adjusted Life Years*
  • Surveys and Questionnaires*
  • Tenecteplase
  • Thrombolytic Therapy
  • Time Factors
  • Time-to-Treatment
  • Tissue Plasminogen Activator / administration & dosage
  • Treatment Outcome


  • Fibrinolytic Agents
  • Tissue Plasminogen Activator
  • Tenecteplase

Associated data